New Cancer Immunotherapy Agents in Development
Wednesday, November 9, 2016

Primer on Tumor Immunology and Cancer Immunotherapy™
Thursday, November 10, 2016

Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy
Thursday, November 10, 2016

31st Annual Meeting
Friday, November 11–Sunday, November 13, 2016

Value of Cancer Immunotherapy Summit
Organized in Collaboration with the American Society of Clinical Oncology (ASCO)
Sunday, November 13, 2016
New Cancer Immunotherapy Agents in Development

**Wednesday, November 9, 2016**

**Co-Chairs:**
- Adrian Bot, MD, PhD – **Kite Pharma, Inc.**
- Daniel S. Chen, MD, PhD – **Genentech**
- Roger D. Dansey, MD – **Merck & Co., Inc.**
- Ramy Ibrahim, MD* – **The Parker Institute for Cancer Immunotherapy**
  *Formerly at AstraZeneca
- Salil Patel, PhD – **Bristol-Myers Squibb**

11:00 – 11:10 a.m. **Welcome & Introductions**
Daniel Chen, MD, PhD – **Genentech**

**Session I: Clinical New Agents in Development**

**Moderator:**
Adrian Bot, MD, PhD – **Kite Pharma, Inc.**

11:10 – 11:15 a.m. **Anti-Semaphorin4D VX15/2503 in Combination with Ipilimumab or Antibody to PD-1 or PD-L1**
Elizabeth Evans, PhD – **Vaccinex, Inc.**
Vice President Preclinical Research

11:15 – 11:20 a.m. **IMO-2125, an Investigational Intratumoral Toll-Like Receptor 9 Agonist, Modulates the Tumor Microenvironment to Enhance Anti-tumor Immunity**
Mark Cornfeld, MD, MPH – **Idera Pharmaceuticals**
Vice President, Oncology Medical Lead

11:20 – 11:25 a.m. **Cobimetinib in Combination with Atezolizumab**
Edward Cha, MD, PhD – **Genentech**
Associate Medical Director

11:25 – 11:30 a.m. **Combination Strategy for Varilumab, An Agonist Anti-CD27 Monoclonal Antibody**
Thomas Davis, MD – **Celldex Therapeutics, Inc.**
Chief Medical Officer

11:30 – 11:35 a.m. **Safety of the Natural Killer (NK) Cell-Targeted Anti-KIR Antibody, Lirilumab (liri), in Combination with Nivolumab (nivo) or Ipilimumab (ipi) in Two Phase 1 Studies in Advanced Refractory Solid Tumors**
Rom S. Leidner, MD – **Earle A. Chiles Research Institute, Providence Cancer Center**
Attending Physician
11:35 – 11:40 a.m.  A CD122-Biased Agonist Increases CD8+T Cells and Natural Killer Cells in the Tumor Microenvironment; Making Cold Tumors Hot with NKTR-214
Adi Diab, MD – The University of Texas MD Anderson Cancer Center
Assistant Professor

11:40 – 11:45 a.m.  Activated Natural Killer (aNK) Cell Therapy
Patrick Soon-Shiong, MD, FRCS, FACS – NantKwest
CEO & Chairman

Session II: Pre-Clinical New Agents in Development
Moderator:
Adrian Bot, MD, PhD – Kite Pharma, Inc.

11:45 – 11:50 a.m.  CD3-EGFR Probody™ T Cell-Engaging Bispecific Induces Tumor Regressions and Substantially Increases Safety Window in Preclinical Studies
Bryan A. Irving, PhD – CytomX Therapeutics, Inc.
Vice President

11:50 – 11:55 a.m.  PRS-343, a CD137 (4-1BB)/HER2 Bispecific
Shane A. Olwill, PhD – Pieris Pharmaceuticals, Inc.
VP Development and Head of Immuno-oncology

Thomas W. Dubensky Jr., PhD – Aduro Biotech
Chief Scientific Officer

Noon – 12:05 a.m.  CA170: A Small Molecule Orally Available Checkpoint Inhibitor
David Tuck, MD – Curis
Chief Medical Officer

12:05 – 12:10 p.m.  LAG-3lg (IMP321) in Combination with Anti-PD-1 Therapy
Frederic Triebel, MD, PhD – Prima Biomed
Chief Scientific Officer and Chief Medical Officer

12:10 – 12:15 p.m.  Agent A - PD-1 DNR-41BB: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation
Prasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer Center
Deputy Chief, Translational and Clinical Research

12:15 – 12:20 p.m.  The Immunoreceptor TIGIT Regulates Anti-Tumor Immunity
Jane Grogan, PhD – Genentech
Principle Scientist

12:20 – 12:45 p.m.  Audience Q & A

12:45 – 1:30 p.m.  Lunch
Session III: Strategic Considerations of Combinations and Biomarkers in New Agent Development

1:30 – 2:00 p.m.  
**Combinations & Biomarkers**  
Charles G. Drake, MD, PhD – *Columbia University Herbert Irving Comprehensive Cancer Center*

2:00 – 3:25 p.m.  
**Extended Panel Discussion**  
*Moderator:* Daniel S. Chen, MD, PhD – Genentech

*Clinical Representative:*  
Charles G. Drake, MD, PhD – *Columbia University Herbert Irving Comprehensive Cancer Center*

*Translational Representative:*  
Gordon J. Freeman, PhD – *Dana-Farber Cancer Institute*

*FDA Representatives:*  
Raj K. Puri, MD, PhD – *U.S. Food & Drug Administration*  
Marc Theoret, MD – *U.S. Food & Drug Administration*

3:25 – 3:30 p.m.  
**Closing Remarks**  
Roger D. Dansey, MD – *Merck & Co., Inc.*

Social Activity

3:30 – 4:30 p.m.  
**Drug Development Networking Reception**
Session I: Basic Immunology – A Brief Overview
2 AMA PRA Category 1 Credits™

8:10 – 8:45 a.m.  Introduction to Innate Immunity
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

8:45 – 9:20 a.m.  Overview of Adaptive Immunity
Jonathan Powell, MD, PhD – Johns Hopkins Hospital

9:20 – 9:55 a.m.  Obstacles to Driving an Immune Response
Nicholas Arpaia, PhD – Columbia University Medical Center

9:55 – 10:10 a.m.  Panel Questions & Answers

10:10 – 10:25 a.m.  Break

Session II: Treating Tumors with Passive Immunotherapy
2 AMA PRA Category 1 Credits™

10:25 – 10:30 a.m.  Session II Introduction
Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center

10:30 – 11:05 a.m.  Adoptive T Cell Therapy
Saar I. Gill, MD, PhD – University of Pennsylvania

11:05 – 11:40 a.m.  Monoclonal Antibodies and Bi-Specifics/Structure and Mechanism of Action
Charles G. Drake, MD, PhD – Columbia University Herbert Irving Comprehensive Cancer Center

11:40 – 12:15 p.m.  Cytokines: Interferons, Interleukins and Beyond
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center

12:15 – 12:30 p.m.  Panel Questions & Answers

12:30 – 1:30 p.m.  Lunch
Session III: Active Immunotherapy – Unleashing the Patient’s Own Immune System
1.5 AMA PRA Category 1 Credits™

1:30 – 1:35 p.m.  
**Session III Introduction**  
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

1:35 – 2:10 p.m.  
**Cancer Vaccines**  
Patrick Ott, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School

2:10 – 2:45 p.m.  
**Targeting Regulatory Molecules in Cancer Therapy: New Insights and Opportunities**  
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

2:45 – 3:00 p.m.  
**Panel Questions & Answers**

3:00 – 3:15 p.m.  
**Break**

Session IV: Figuring out How it All Works and Future Directions
1.75 AMA PRA Category 1 Credits™

3:15 – 3:20 p.m.  
**Session IV Introduction**  
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

3:20 – 3:55 p.m.  
**Immune Monitoring and Next Generation**  
Sacha Gnjatic, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

3:55 – 4:30 p.m.  
**Single-cell Analysis of Tumor Infiltrating T Cells in Human Colorectal Cancer**  
Arnold Han, MD, PhD – Columbia University Medical Center

4:30 – 4:45 p.m.  
**Panel Questions & Answers**

4:45 – 5:00 p.m.  
**Closing Remarks**  
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Social Activity

5:30 – 6:30 p.m.  
**Presidential Reception & State of SITC: Membership Business Meeting**
Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy

Thursday, November 10, 2016

8:00 – 8:05 a.m. Welcome & Introductions
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

Session I: Introduction to Models of Immunotherapy
2.0 AMA PRA Category 1 Credits™

8:05 – 8:35 a.m. Major Questions Related to Immunotherapies that Require Models to Address
Mario Sznol, MD – Yale School of Medicine

8:35 – 9:05 a.m. Overview of Mouse-Mouse Models
Marcus W. Bosenberg, MD, PhD – Yale School of Medicine

9:05 – 9:35 a.m. Overview of Humanized Mice Models
A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine

9:35 – 10:05 a.m. Overview of Patient-derived Xenograft (PDX) Models
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

10:05 – 10:35 a.m. Break

Session II: Modeling the Tumor Microenvironment
2.0 AMA PRA Category 1 Credits™

10:35 – 11:05 a.m. Evaluation of the Tumor Microenvironment
Mark B. Headley, PhD – University of California San Francisco

11:05 – 11:35 a.m. Factors Affecting Tumor – Microenvironment Interactions
Lisa M. Coussens, PhD – Oregon Health and Sciences University

11:35 – 12:05 p.m. Vascular Regulation of the Tumor Microenvironment and Immune Responses
Amanda Lund, PhD – Oregon Health & Science University

12:05 – 12:35 p.m. Components of the Tumor Microenvironment that Module Tumor Immune Responses
Kwok-Kin Wong, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School

12:35 – 1:25 p.m. Lunch
Session III: Modeling Evaluation of Immune Therapies

1.75 AMA PRA Category 1 Credits™

1:25 – 2:00 p.m. Evaluation of Immune Checkpoint Inhibitors in Mice
Arlene H. Sharpe, MD, PhD – Harvard Medical School

2:00 – 2:35 p.m. Reevaluating the Role of IDOI in Brain Cancer; Humanized Immunocompetent Mice Take Center Stage
Derek A. Wainwright, PhD – Northwestern University

2:35 – 3:10 p.m. Developing New Immunotherapies in Preclinical Models and Humans
Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

3:10 – 3:45 p.m. What Information Provided by Models will Inform Immune Drug Development and Use?
Non-CE Presentation
Philip Gotwals, PhD – Novartis Institutes for BioMedical Research, Inc.

3:45 – 4:05 p.m. Break

Session IV: Panel Discussion and Future Directions

4:05 – 4:45 p.m. Future Directions for the Development and Use of Cancer Immune Models
Moderator: Marcus W. Bosenberg, MD, PhD – Yale School of Medicine

Panelists:
Lisa M. Coussens, PhD – Oregon Health and Sciences University
Philip Gotwals, PhD – Novartis Institutes for BioMedical Research, Inc.
Elizabeth M. Jaffee, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
A. Karolina Palucka, MD, PhD – The Jackson Laboratory for Genomic Medicine
Arlene H. Sharpe, PhD – Harvard Medical School
Mario Sznol, MD – Yale School of Medicine
Kwok-Kin Wong, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

4:45 – 5:00 p.m. Closing Remarks
Marcus W. Bosenberg, MD, PhD – Yale School of Medicine

Social Activity

5:30 – 6:30 p.m. Presidential Reception & State of SITC: Membership Business Meeting
31st Annual Meeting

Friday, November 11, 2016

7:30 – 7:35 a.m.  Presidential Welcome
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Holbrook Edwin Kidd Kohrt, MD, PhD Tribute*
Non-CE Session

7:35 – 8:00 a.m.  Organizers & Speakers
Daniel S. Chen, MD, PhD – Genentech
Amani Makkouk, PhD – Calithera Biosciences
Ignacio Melero, MD, PhD – University of Navarra
Russell Pachynski, MD – Washington University School of Medicine

Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes
0.25 AMA PRA Category 1 Credits™

Chair:
Mac Cheever, MD – Fred Hutchinson Cancer Research Center

8:00 – 8:05 a.m.  Anti-PD1 in Merkel Cell Cancer and in Malignancy with HIV, IL7 in Prostate Cancer, Anti-CD40 in Pancreas Cancer
Mac Cheever, MD – Fred Hutchinson Cancer Research Center

8:05 a.m. – 8:10 a.m.  Anti-PD1 in Mycosis Fungoides/Sezary Syndrome
Michael Khodadoust, MD – Stanford University

8:10 a.m. – 8:15 a.m.  IL15 in Solid Tumors
Jeffrey S. Miller, MD – University of Minnesota

8:15 a.m. – 8:20 a.m.  IDO Inhibitor in Ovarian Cancer and Melanoma
Kunle Odunsi, MD, PhD – Roswell Park Cancer Institute Center for Immunotherapy

8:20 a.m. – 8:25 a.m.  Flt3-L with Poly ICLC and Anti-DEC205-NY-ESO-1 in Melanoma
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Mount Sinai Medical Center

Keynote Address: The Mechanistic Basis of Cancer Immunotherapy
Non-CE Session

8:25 – 8:30 a.m.  Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

8:30 – 9:05 a.m.  The Mechanistic Basis of Cancer Immunotherapy
Ira Mellman, PhD – Genentech

9:05 – 9:10 a.m.  Question & Answer
Ira Mellman, PhD – Genentech
Tumor Microenvironment
2.25 AMA PRA Category 1 Credits™

Co-Chairs:
Mary L. (Nora) Disis, MD – University of Washington
Thomas F. Gajewski, MD, PhD – University of Chicago

9:10 – 9:15 a.m.  
Introduction  
Mary (Nora) L. Disis, MD – University of Washington

9:15 – 9:40 a.m.  
Tumor Microenvironment with Clinical Aspect; Impact of Therapeutics on Microenvironment  
George Coukos, MD, PhD – University Hospital of Lausanne

9:40 – 10:05 a.m.  
Immunomodulatory Roles of Lymphatic Vessels in the Tumor Microenvironment  
Melody Swartz, PhD – University of Chicago

10:05 – 10:25 a.m.  
Break

10:25 – 10:50 a.m.  
CD4 T Cells as Regulators of Tumor Growth  
Mary (Nora) L. Disis, MD – University of Washington

10:50 – 11:05 a.m.  
Neuropilin-1-Deficient Regulatory T cell-Derived Interferon-γ Drives Infectious Instability and Tumor Clearance  
Abigail E. Overacre – University of Pittsburgh

11:05 – 11:30 a.m.  
Tumor and Host Factors Influencing Immune Regulation Within the Tumor Microenvironment  
Thomas F. Gajewski, MD, PhD – University of Chicago

11:30 – 11:45 a.m.  
CD8α+ Dendritic Cells Regulate Leukemia Antigen-Specific CD8+ T Cell Tolerance  
Justin P. Kline, MD – University of Chicago

Late-Breaking Abstract Session I
Non-CE Session

Chair:
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute

11:45 – 12:00 p.m.  
Computational Identification, Functional Characterization and Antibody Blockade of a New Immune Checkpoint in the TIGIT Family of Interacting Molecules  
John Hunter, PhD – Compugen USA, Inc.

12:00 – 12:15 p.m.  
Combinatorial CD8+ and PD-L1 + Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab  
Sonja Althammer, PhD – Definiens

12:15 – 1:30 p.m.  
Lunch and Poster Viewing

Update Session: Government Agencies
0.5 AMA PRA Category 1 Credits™

Chair:
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health

1:30 – 1:45 p.m.  
National Cancer Institute  
T. Kevin Howcroft, PhD – National Cancer Institute, National Institutes of Health
1:45 – 2:00 p.m.  
**U.S. Food & Drug Administration**  
Raj K. Puri, MD, PhD – **U.S. Food & Drug Administration**

**State-of-the-Art Immunotherapies: Challenges and Opportunities**  
2.25 AMA PRA Category 1 Credits™

**Co-Chairs:**  
James L. Gulley, MD, PhD, FACP – **National Cancer Institute, National Institutes of Health**  
Roy S. Herbst, MD, PhD – **Yale Cancer Center**

2:00 – 2:05 p.m.  
**Introduction**  
James L. Gulley, MD, PhD, FACP – **National Cancer Institute, National Institutes of Health**

2:05 – 2:30 p.m.  
**Challenges and Opportunities for Immunotherapy in Prostate Cancer**  
James L. Gulley, MD, PhD, FACP – **National Cancer Institute, National Institute of Health**

2:30 – 2:55 p.m.  
**Melanoma: Challenges and Opportunities and the Need for Rational Combinations of Agents**  
Patrick Hwu, MD – **University of Texas MD Anderson Cancer Center**

2:55 – 3:05 p.m.  
**Phase I/II CANON Study: Oncolytic Immunotherapy for the Treatment of Non-muscle Invasive Bladder (NMIBC) Cancer Using Intravesical Coxsackievirus A21**  
Nicola E. Annels, BSc, PhD – **University of Surrey**

3:05 – 3:15 p.m.  
**IL-1S Primes an mTOR-Regulated Gene-expression Program to Prolong Anti-tumor Capacity of Human Natural Killer Cells**  
Andreas Lundqvist – **Karolinska Institutet**

3:15 – 3:25 p.m.  
**Reactivating the Anti-tumor Immune Response by Targeting Innate and Adaptive Immunity in a Phase I/II Study of Intratumoral IMO-2125 in Combination with Systemic ipilimumab in Patients with Anti-PD-1 Refractory Metastatic Melanoma**  
Cara Haymaker, PhD – **University of Texas MD Anderson Cancer Center**

3:25 – 3:50 p.m.  
**Translational Development of Novel Immunotherapies for Hematologic Cancers**  
Larry W. Kwak, MD, PhD – **City of Hope National Medical Center**

3:50 – 4:15 p.m.  
**Lung Cancer: Frontline Cancer, Predictive Markers, and Novel Combinations**  
Roy S. Herbst, MD, PhD – **Yale Cancer Center**

4:15 – 4:45 p.m.  
**Break**

---

**Concurrent Session 1: Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity**  
1.5 AMA PRA Category 1 Credits™

*Organized in collaboration with the American Society for Cell Biology (ASCB)*

**Co-Chairs:**  
Tom Misteli, PhD – **National Cancer Institute, National Institutes of Health**  
Graham P. Pawelec, PhD – **University of Tuebingen**

4:45 – 4:50 p.m.  
**Introduction**  
Graham P. Pawelec, PhD – **University of Tuebingen**

4:50 – 5:15 p.m.  
**The Immune System Strikes Back: T Cells Recognizing Indoleamine 2,3-Dioxygenase (IDO) or PD-L1**  
Mads Hald Andersen, PhD – **Herlev University Hospital**
Myeloid-Derived Suppressor Cells (MDSC), Age and Cancer
Dawn Bowdish, PhD – McMaster University

NAD-Sirt1 Axis is Central to the Unique Immuno-Metabolic Phenotype of Th1/17 Hybrid Cells in Regulating its Enhanced Anti-tumor Potential
Shilpak Chatterjee, PhD – Medical University of South Carolina

The Wnt5a-beta-catenin Pathway Triggers a Metabolic Switch that Drives Indoleamine 2,3-Dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment: Optimizing Checkpoint Inhibitor Immunotherapy
Brent A. Hanks, MD, PhD – Duke University Medical Center

Concurrent Session II: Promoting and Measuring Antitumor Immunity
1.25 AMA PRA Category 1 Credits™

Co-Chairs:
Francesco M. Marincola, MD – Sidra Medical and Research Center
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health

Introduction
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health

Immunotherapeutics and Analyses of the Peripheral Immunome
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health

Vaccines, Tumor Antigens, and Immune Responses
Lisa H. Butterfield, PhD – University of Pittsburgh

Deciphering Human T Cell Immune Responses Modulated with Immunotherapy
Lawrence Fong, MD – University of California, San Francisco

Immunoscore® Colon Analytical Performance
Fabienne Hermitte, PhD – HalioDx

Closing Remarks
Francesco M. Marincola, MD – Sidra Medical and Research Center

Social Activity
Poster Reception
Saturday, November 12, 2016

Update Session: Society Initiatives

7:30 – 7:40 a.m.  Immune Biomarkers Task Force Update
Lisa H. Butterfield, PhD – University of Pittsburgh

7:40 – 7:55 a.m.  Immunoscore as a Prognostic Marker in Stage I-III Colon Cancer: Results of a SITC-Led Global Validation Study
Jérôme Galon, PhD – INSERM – Cordeliers Research Center

Richard Smalley, MD Memorial Lectureship
.75 AMA PRA Category 1 Credits™

7:55 – 8:00 a.m.  Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

8:00 – 8:35 a.m.  Smalley Keynote Address: PD-1 Blockade in Cancer Treatment – Immunotherapy Meets Precision Medicine
Suzanne L. Topalian, MD – Johns Hopkins University

8:35 – 8:40 a.m.  Question & Answer
Suzanne L. Topalian, MD – Johns Hopkins University

Beyond Single-Agents: The Future of Combination Immunotherapy
2.0 AMA PRA Category 1 Credits™

Co-Chairs:
Drew M. Pardoll, MD, PhD – Johns Hopkins University
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
Holbrook E. Kohrt, MD, PhD* – Stanford Cancer Institute

8:40 – 8:45 a.m.  Introduction
F. Stephen Hodi, MD – Dana-Farber Cancer Institute

8:45 – 9:10 a.m.  Combination Development
Ignacio Melero, MD, PhD – University of Navarra

9:10 – 9:35 a.m.  Next Generation Anti-CTLA-4 Antibodies
Alan J. Korman, PhD – Bristol-Myers Squibb Company

9:35 – 10:00 a.m.  Combination in Patient Selection
Jérôme Galon, PhD – INSERM – Cordeliers Research Center

10:00 – 10:20 a.m.  Break

10:20 – 10:40 a.m.  Combinations and Influences on Biomarkers
Drew M. Pardoll, MD, PhD – Johns Hopkins University

10:40 – 10:55 a.m.  Clinical Safety and Efficacy Assessment of the CD137 Agonist Urelumab Alone and in Combination with Nivolumab in Patients with Hematologic and Solid Tumor Malignancies
Erminia Massarelli, MD, PhD, MS – City of Hope

10:55 – 11:10 a.m.  Beyond Immune Checkpoint: First-in-Class Antibody Targeting Soluble NKG2D Ligand sMIC for Cancer Immunotherapy
Jennifer Wu, PhD – Medical University of South Carolina
11:10 – 11:15 a.m. Closing Remarks
Drew M. Pardoll, MD, PhD – Johns Hopkins University

Late-Breaking Abstract Session II
Non-CE Session

Chair: Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute

11:15 – 11:30 a.m. Preliminary Efficacy from a Phase I/II Study of the Natural Killer Cell-Targeted Antibody, Lirilumab in Combination with Nivolumab in Squamous Cell Carcinoma of the Head and Neck
Rom Leidner, MD – Earl A. Chiles Research Institute, Providence Cancer Center

11:30 – 11:45 a.m. Efficacy and Safety of Nivolumab Plus Ipilimumab in Metastatic Urothelial Carcinoma: First Results From the Phase I/II From the Phase I/II CheckMate 032 Study
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center

11:45 – noon KEYNOTE-045: Open-label, Phase 3 Study of Pembrolizumab versus Investigator’s Choice of Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Advanced Urothelial Cancer
Joaquim Bellmunt, MD, PhD – Dana-Farber, Brigham and Women’s Cancer Center, Harvard Medical School

Noon – 1:00 p.m. Lunch and Poster Viewing

Concurrent Session I: Presidential Session
1.25 AMA PRA Category 1 Credits™

Chair: Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

1:00 – 1:05 p.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

1:05 – 1:20 p.m. Intestinal Microbiota and Relapse after Hematopoietic-cell Transplantation
Jonathan Peled, MD, PhD – Memorial Sloan Kettering Cancer Center

1:20 – 1:35 p.m. Mitochondrial Biogenesis is Repressed in Tumor-infiltrating CD8+ T cells Resulting in Metabolic Insufficiency and T Cell Dysfunction
Nicole E. Scharping – University of Pittsburgh

1:35 – 1:45 p.m. Expert Discussant
Drew M. Pardoll, MD, PhD – Johns Hopkins University

1:45 – 2:00 p.m. Increased STAT3 Signaling and Decreased Suppressive Function of Regulatory T Cells are Biomarkers of Positive Patient Outcome to Nivolumab Therapy
David M. Woods, PhD – New York University

2:00 – 2:15 p.m. Analysis of Pharmacodynamic Biomarkers in the First In-Human Trial of GITR Co-Stimulation with the Agonist Antibody TRX-518 in Advanced Solid Cancer Patients
Roberta Zappasodi, PhD – Memorial Sloan Kettering Cancer Center

2:15 – 2:25 p.m. Expert Discussant
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)
1.5 AMA PRA Category 1 Credits™

Co-Chairs:
Satiro N. De Oliveira, MD – University of California, Los Angeles
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

1:00 – 1:05 p.m. Introduction
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

1:05 – 1:30 p.m. Immunology 101 for the Non-Immunologist
Christian Capitini, MD – University of Wisconsin, Madison

1:30 – 1:55 p.m. Basic Principles of Tumor Immunotherapy
Satiro N. De Oliveira, MD – University of California Los Angeles

1:55 – 2:20 p.m. Tumor Immunotherapy on the Horizon
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

2:20 – 2:25 p.m. Closing Remarks
Satiro N. De Oliveira, MD – University of California Los Angeles

2:25 – 2:40 p.m. Break

Concurrent Session I: Microbiome and the Impact on Local Inflammation and Host Immunity
1.75 AMA PRA Category 1 Credits™

Co-Chairs:
Lisa M. Coussens, PhD – Oregon Health and Science University
Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health

2:40 – 2:45 p.m. Introduction
Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health

2:45 – 3:10 p.m. Microbial Modulation of Mononuclear Phagocytes in Cancer Therapy
Romina Goldszmid, PhD – National Cancer Institute, National Institutes of Health

3:10 – 3:35 p.m. Influence of Microbiome on Efficacy of Anti-Cancer Therapy
María Paula Roberti, PhD – Institute Gustave Roussy

3:35 – 4:00 p.m. Inflammation Fuels Microbial Carcinogenic Activities
Christian Jobin, PhD – University of Florida

4:00 – 4:15 p.m. Pre-existing Immunity to Oncolytic Virus Potentiates its Therapeutic Efficacy
Jacob Ricca – Memorial Sloan Kettering Cancer Center

4:15 – 4:20 p.m. Closing Remarks
Lisa M. Coussens, PhD – Oregon Health and Science University
Concurrent Session II: Clinical Management (Nurse/Pharmacist Track)
1.75 AMA PRA Category 1 Credits™

Co-Chairs:
Matthew Burke, MBA, RN, MSN, APRN-B – Stanford Health Care
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute

2:40 – 2:45 p.m.  Introduction
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute

2:45 – 3:05 p.m.  Immunotherapy Agents Currently Approved for the Treatment of Cancer
Kristen Kreamer, CRNP, MSN, AOCNP, APRN-BC – Fox Chase Cancer Center

3:05 – 3:25 p.m.  Assessment & Management of irAEs
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital Cancer Center

3:25 – 3:45 p.m.  Management of Complex Adverse Events: Case Studies
Brianna W. Hoffner, BA, MSN, RN, ANP-BC – University of Colorado Cancer Center

3:45 – 4:00 p.m.  Incidence and Outcomes of Central Nervous System Metastasis in Metastatic Melanoma Patients Treated with Anti-PD1 Therapy
Gustavo Schvartsman, MD – University of Texas MD Anderson Cancer Center

4:00 – 4:15 p.m.  Audience Question & Answer
Moderator: Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute

4:15 – 4:20 p.m.  Closing Remarks
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute

4:20 – 4:50 p.m.  Break

Concurrent Session I: Diet, Exercise, Stress and the Impact on the Immune System
1.5 AMA PRA Category 1 Credits™
Organized in collaboration with the Society of Behavioral Medicine (SBM)

Co-Chairs:
Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
Connie J. Rogers, PhD, MPH – Pennsylvania State University

4:50 – 4:55 p.m.  Introduction
Connie J. Rogers, PhD, MPH – Pennsylvania State University

4:55 – 5:15 p.m.  Changes in Energy Balance Modulate the Immune Response in Breast Cancer Risk & Progression
Connie J. Rogers, PhD, MPH – Pennsylvania State University

5:15 – 5:35 p.m.  Research in Behavior in Cancer and Cancer Treatment
Dana H. Bovbjerg, PhD – University of Pittsburgh Cancer Institute

5:35 – 5:55 p.m.  Effects of Behavioral Stress on the Tumor Microenvironment
Susan K. Lutgendorf, PhD – University of Iowa

5:55 – 6:10 p.m.  β-Adrenergic Signaling Induced by Cool Housing Temperatures Mediates Immune Suppression and Impairs the Efficacy of Anti-PD-1 Checkpoint Blockade Immunotherapy in Laboratory Mice
Mark J. Bucsek – Roswell Park Cancer Institute
6:10 – 6:15 p.m.  
**Closing Remarks**  
Elizabeth A. Repasky, PhD – *Roswell Park Cancer Institute*

**Concurrent Session II: Adoptive Cellular Therapy vs. Bispecific Antibodies**  
1.5 AMA PRA Category 1 Credits™

Co-Chairs:  
Crystal L. Mackall, MD – *Stanford University*  
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

4:50 – 4:55 p.m.  
**Introduction**  
Crystal L. Mackall, MD – *Stanford University*

4:55 – 5:15 p.m.  
**CARs - CD19 and Beyond**  
Crystal L. Mackall, MD – *Stanford University*

5:15 – 5:35 p.m.  
**Bispecific T Cell Engagers, Biology and Clinical Application**  
Max S. Topp, MD – *Universitatsklinikum Wurzburg*

5:35 – 5:55 p.m.  
**CAR Designs for Safe and Effective T Cell Therapy**  
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

5:55 – 6:10 p.m.  
**Clinical Responses in Advanced Pancreatic Patients Treated with Bispecific Antibody Armed T Cells (BATS)**  
Lawrence G. Lum, MD, DSc – *University of Virginia Cancer Center*

6:10 – 6:15 p.m.  
**Closing Remarks**  
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

**Concurrent Session III: Emerging Technologies**  
Non-CE Session

Co-Chairs:  
Edward C. Stack, PhD – *PerkinElmer*  
David A. Zaharoff, PhD – *University of North Carolina, Chapel Hill & North Carolina State University*

4:50 – 4:55 p.m.  
**Introduction**  
Edward C. Stack, PhD – *PerkinElmer*

4:55 – 5:20 p.m.  
**Understanding T Cells, Macrophages, and Expression of PD-1/PD-L1 in Hodgkin’s Lymphoma**  
Scott J. Rodig, MD, PhD – *Brigham and Women’s Hospital, Harvard Medical School*

5:20 – 5:40 p.m.  
**Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity**  
Darrell J. Irvine, PhD – *Massachusetts Institute of Technology*

5:40 – 5:55 p.m.  
**Mechanisms of Chitosan/IL-12 Immunotherapy for the Treatment of Bladder Cancer**  
Sean G. Smith – *University of North Carolina - Chapel Hill & North Carolina State University*

5:55 – 6:10 p.m.  
**ImmunoMap: A Novel Bioinformatics Tool for Analysis of T cell Receptor Repertoire Data in Model Systems and Clinical Settings**  
John-William Sidhom – *Johns Hopkins University*
6:10 – 6:15 p.m.  Closing Remarks  
David A. Zaharoff, PhD – University of North Carolina - Chapel Hill & North Carolina State University

Social Activities

6:15 – 6:45 p.m.  Award Ceremony
6:45 – 8:00 p.m.  Poster Reception
Value of Cancer Immunotherapy Summit
Organized in collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 201
Non CE-session

Co-Chairs:
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Lowell E. Schnipper, MD – Beth Israel Deaconess Medical Center
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute

7:45 – 7:50 a.m.  Annual Meeting Organizer Welcome
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institute of Health

7:50 – 8:00 a.m.  Program Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 – 8:30 a.m.  Evaluation of Current Value Models
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute

8:30 – 8:45 a.m.  Cancer Immunotherapy Perspective on Current Value Models
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center

8:45 – 9:05 a.m.  Economic Outcomes of Cancer Therapy: ISPOR Initiatives on U.S. Value Assessment Framework
Lou Garrison, PhD, AB – University of Washington

9:05 – 9:25 a.m.  Patient Perspective
Steven Silverstein, MBA – Melanoma Research Foundation

9:25 – 9:45 a.m.  Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute

9:45 – 10:10 a.m.  Panel Discussion
Moderator:
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Panelists:
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Lou Garrison, PhD, AB – University of Washington
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute
Steven Silverstein, MBA – Melanoma Research Foundation
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute
Session II: Perspectives on the Value of Cancer Immunotherapy

10:10 – 10:30 a.m.  
**Payor Perspective**  
William McGivney, PhD – McGivney Global Advisors

10:30 – 10:50 a.m.  
**Industry Perspective**  
Jon M. Wigginton, MD – MacroGenics, Inc.

10:50 – 11:10 a.m.  
**Predictive and Companion Biomarkers**  
Roy S. Herbst, MD, PhD – Yale Cancer Center

11:10 – 11:55 a.m.  
**Panel Discussion**  
*Moderator:*  
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center

*Panelists:*  
Kirsten Axelsen, MS – Pfizer  
Daniel S. Chen, MD, PhD – Genentech  
Ravinder Dhawan, PhD – Merck & Co  
Roy S. Herbst, MD, PhD – Yale Cancer Center  
Gregory Keenan, MD – AstraZeneca  
William McGivney, PhD – McGivney Global Advisors  
Jon M. Wigginton, MD – MacroGenics, Inc.

11:55 – noon  
**Closing Remarks**

*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)*  
Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC. Dr. Kohrt was actively involved in the development of SITC’s 31st Annual Meeting as an Organizer and session Co-Chair up until the time of passing. As such, the 31st Annual Meeting will contain a fitting tribute to his memory and his many contributions to the field.